Liberman Joshua N, Bhattacharjee Sandipan, Rui Pinyao, Ruetsch Charles, Rothman Brian, Kulkarni Amit, Forma Felicia
Health Analytics, LLC, USA.
Otsuka Pharmaceutical Development & Commercialization, Inc, USA.
Health Serv Res Manag Epidemiol. 2022 Jul 6;9:23333928221111864. doi: 10.1177/23333928221111864. eCollection 2022 Jan-Dec.
To estimate the impact COVID-19 pandemic on healthcare resource utilization (HCRU) among individuals with major depressive disorder (MDD).
A retrospective cohort study was conducted to compare HCRU in the twelve months prior to and six months following pandemic onset among 1,318,709 individuals with MDD and propensity-score matched controls. Outcomes were monthly rates of all-cause and MDD-specific outpatient, inpatient, and prescription medication HCRU. Piecewise random effects models were used to adjust for patient-level clustering, trends over time, and pre-pandemic factors.
In the first month following onset, outpatient HCRU declined with primary care visits down 25.1%. Following this initial decline, outpatient HCRU increased, exceeding pre-pandemic rates within three months. By April 2020, three quarters of all psychotherapy sessions were delivered by telehealth, followed by psychiatry (62.3%), and primary care visits (30.1%). The use of telehealth remained highest for psychotherapy and psychiatry (representing 67.6% and 54.2% of visits, respectively, in September 2020). All-cause partial-day hospitalizations declined 50.5% and remained depressed through July 2020 (down 18.3%). Beginning in the first month post-onset, prescription medication HCRU increased for all antidepressant and antipsychotic medication classes: serotonin modulators ( + 11.8%), bupropion ( + 10.4%), SSRIs ( + 9.0%), SNRIs ( + 8.6%), and atypical antipsychotics ( + 7.5%).
Following pandemic onset, individuals with MDD realized an immediate, but short-lived, reduction in primary care HCRU. Telehealth use remained elevated through the first six months. The most significant and sustained reduction in HCRU was noted for partial-day hospitalizations and all-cause ED visits.
评估2019冠状病毒病(COVID-19)大流行对重度抑郁症(MDD)患者医疗资源利用(HCRU)的影响。
开展一项回顾性队列研究,比较1318709例MDD患者及其倾向得分匹配对照在大流行开始前十二个月和开始后六个月的HCRU情况。结局指标为全因及MDD特异性门诊、住院和处方药HCRU的月发生率。采用分段随机效应模型对患者层面的聚类、随时间的趋势以及大流行前因素进行校正。
在发病后的第一个月,门诊HCRU下降,初级保健就诊次数下降25.1%。在这一初始下降之后,门诊HCRU增加,在三个月内超过了大流行前的水平。到2020年4月,四分之三的心理治疗疗程通过远程医疗提供,其次是精神病学(62.3%)和初级保健就诊(30.1%)。远程医疗在心理治疗和精神病学中的使用仍然最高(分别占2020年9月就诊次数的67.6%和54.2%)。全因部分日间住院次数下降50.5%,到2020年7月仍处于较低水平(下降18.3%)。从发病后的第一个月开始,所有抗抑郁药和抗精神病药物类别的处方药HCRU均增加:血清素调节剂(+11.8%)、安非他酮(+10.4%)、选择性5-羟色胺再摄取抑制剂(SSRI,+9.0%)、5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)(+8.6%)和非典型抗精神病药物(+7.5%)。
大流行开始后,MDD患者的初级保健HCRU立即出现但短暂下降。远程医疗的使用在头六个月一直居高不下。HCRU下降最显著且持续的是部分日间住院和全因急诊就诊。